161 related articles for article (PubMed ID: 36261902)
61. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Craiglow BG; King BA
JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
[TBL] [Abstract][Full Text] [Related]
62. [Development of new topical substances for the treatment of atopic dermatitis].
Freimooser S; Traidl S; Werfel T
Dermatologie (Heidelb); 2022 Jul; 73(7):514-519. PubMed ID: 35608634
[TBL] [Abstract][Full Text] [Related]
63. Olumiant
Gupta AK; Wang T; Vincent K; Abramovits W
Skinmed; 2022; 20(6):452-455. PubMed ID: 36537681
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K; Peeva E; Yamaguchi Y; Cox LA; Banerjee A; Han G; Hamzavi I; Ganesan AK; Picardo M; Thaçi D; Harris JE; Bae JM; Tsukamoto K; Sinclair R; Pandya AG; Sloan A; Yu D; Gandhi K; Vincent MS; King B
J Am Acad Dermatol; 2023 Feb; 88(2):395-403. PubMed ID: 36370907
[TBL] [Abstract][Full Text] [Related]
65. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck.
Sassi F; Cazzaniga S; Tessari G; Chatenoud L; Reseghetti A; Marchesi L; Girolomoni G; Naldi L
Br J Dermatol; 2008 Nov; 159(5):1186-91. PubMed ID: 18717675
[TBL] [Abstract][Full Text] [Related]
66. Photodynamic therapy with low-strength ALA, repeated applications and short contact periods (40-60 minutes) in acne, photoaging and vitiligo.
Serrano G; Lorente M; Reyes M; Millán F; Lloret A; Melendez J; Navarro M; Navarro M
J Drugs Dermatol; 2009 Jun; 8(6):562-8. PubMed ID: 19537381
[TBL] [Abstract][Full Text] [Related]
67. Impacts of exposure to topical calcineurin inhibitors on metabolism in vitiligo infants.
Hu W; Lin F; Lei J; Xu AE
Pediatr Res; 2023 Feb; 93(3):661-665. PubMed ID: 35681095
[TBL] [Abstract][Full Text] [Related]
68. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo.
Sanclemente G; Garcia JJ; Zuleta JJ; Diehl C; Correa C; Falabella R
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1359-64. PubMed ID: 18624857
[TBL] [Abstract][Full Text] [Related]
69. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A.
Westerhof W; Nieuweboer-Krobotova L
Arch Dermatol; 1997 Dec; 133(12):1525-8. PubMed ID: 9420536
[TBL] [Abstract][Full Text] [Related]
70. Treatment of vitiligo by topical calcipotriol.
Chiavérini C; Passeron T; Ortonne JP
J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):137-8. PubMed ID: 12046816
[TBL] [Abstract][Full Text] [Related]
71. A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter.
Park OJ; Park GH; Choi JR; Jung HJ; Oh ES; Choi JH; Lee MW; Chang SE
Clin Exp Dermatol; 2016 Apr; 41(3):236-41. PubMed ID: 26299799
[TBL] [Abstract][Full Text] [Related]
72. Vitiligo treated with topical corticosteroids: children with head and neck involvement respond well.
Cockayne SE; Messenger AG; Gawkrodger DJ
J Am Acad Dermatol; 2002 Jun; 46(6):964-5. PubMed ID: 12063504
[No Abstract] [Full Text] [Related]
73. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor.
Wong GN; Lee S; Foley P
Australas J Dermatol; 2019 Nov; 60(4):e334-e335. PubMed ID: 31012089
[No Abstract] [Full Text] [Related]
74. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F; Meier K; Ghoreschi K
Front Immunol; 2019; 10():2847. PubMed ID: 31849996
[TBL] [Abstract][Full Text] [Related]
75. In brief: New warnings for janus kinase inhibitors.
Med Lett Drugs Ther; 2021 Oct; 63(1634):160. PubMed ID: 34550959
[No Abstract] [Full Text] [Related]
76. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
77. Guidelines for treatment of vitiligo: is an update pending if recommendations for children are not followed?
Möhrenschlager M; Schnopp C; Abeck D
Arch Dermatol; 2000 Sep; 136(9):1173-4. PubMed ID: 10987882
[No Abstract] [Full Text] [Related]
78. Successful treatment of vitiligo in a 6-year-old child by topical anaesthesia and epidermal grafting.
Lee KJ; Lee JH; Lee DY
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):859-60. PubMed ID: 19143901
[No Abstract] [Full Text] [Related]
79. Reply to: "Special editorial: When prescribing Janus Kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication".
King BA; Craiglow BG
J Am Acad Dermatol; 2022 Aug; 87(2):498-499. PubMed ID: 35398217
[No Abstract] [Full Text] [Related]
80. Topical immunotherapy with diphenylcyclopropenone in vitiligo: a preliminary experience.
Aghaei S; Ardekani GS
Indian J Dermatol Venereol Leprol; 2008; 74(6):628-31. PubMed ID: 19171989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
